Medigene Granted Additional Patent for RhuDex® for the Treatment of Autoimmune Diseases
13 Dezembro 2013 - 4:30AM
Medigene AG / Medigene Granted Additional Patent for RhuDex® for
the Treatment of Autoimmune Diseases . Processed and transmitted by
NASDAQ OMX Corporate Solutions. The issuer is solely responsible
for the content of this announcement.
Martinsried/Munich, 13 December
2013. The biotech company Medigene AG (Frankfurt: MDG1, Prime
Standard) announces that the European Patent Office has granted an
additional patent protecting the drug candidate
RhuDex®, which is
currently being developed by Medigene for the treatment of
autoimmune diseases. The term of the patent EP 1991548 granted for
the choline salt in RhuDex® ends in 2027,
with a potential extension of up to five years.
Dr. Frank
Mathias, Chief Executive Officer of Medigene
AG, comments: "This RhuDex® patent
further expands the protection of our phase II drug candidate and
acknowledges Medigene's continuous work on its development
projects."
RhuDex®: Medigene is developing
RhuDex® as an oral,
disease-modifying drug for the treatment of autoimmune diseases.
RhuDex® is a CD80
antagonist that blocks undesired T-cell activation, and thus has an
immunomodulating and anti-inflammatory effect. Safety and
tolerability of RhuDex® has already
been demonstrated in several phase I clinical trials. Medigene has
successfully completed a phase IIa pilot study with
RhuDex® in the
indication rheumatoid arthritis. Currently Medigene is planning to
conduct a phase II trial in primary biliary cirrhosis (PBC), in
order to confirm the mode of action of RhuDex® in
autoimmune diseases.
Primary biliary
cirrhosis (PBC): The autoimmune disease
PBC is a chronic liver disease that initially affects the bile
ducts. The bile ducts are progressively destroyed by inflammatory
processes, causing biliary stasis and build-up of bile in the
liver. Liver tissue is destroyed and replaced by connective tissue,
and liver cirrhosis develops.
Medigene AG
(Frankfurt: MDG, prime standard) is a publicly listed biotechnology
company headquartered in Martinsried/Munich, Germany. Medigene
focuses on clinical research and development of novel drugs against
cancer and autoimmune diseases. Medigene was the first German
biotech company to have revenues from marketed products, which are
distributed by partner companies. It has two drug candidates in
clinical trials, EndoTAG®-1 and
RhuDex®, and is
developing an innovative vaccine technology. For more information,
please visit www.medigene.com.
This press release contains
forward-looking statements representing the opinion of Medigene as
of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of
these forward-looking statements. Medigene® and RhuDex® are registered trademarks of
Medigene AG. These trademarks may be owned or licensed in select
locations only.
Contact
Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com
To unsubscribe from the press
release distribution list, please go to
www.medigene.com/unsubscribe.
Press release as PDF
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medigene AG via Globenewswire
HUG#1749650
Meridian Gold (NYSE:MDG)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Meridian Gold (NYSE:MDG)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
